Analysis of a Systematic Review About Blue Light-Filtering Intraocular Lenses for Retinal Protection: Understanding the Limitations of the Evidence

对用于视网膜保护的蓝光过滤人工晶状体进行系统评价的分析:了解证据的局限性

阅读:1

Abstract

IMPORTANCE: Cataract surgery, with intraocular lens (IOL) implantation, is the most common ocular surgical procedure worldwide. It has been suggested that IOLs that selectively attenuate short wavelength visible light (blue light-filtering IOLs) may be beneficial for macular health. Whether blue light-filtering IOLs impart retinal photoprotection is of public health relevance, particularly in the context of aging demographics and the increasing global prevalence of age-related macular degeneration. This review analyzes and interprets the key findings, including consideration of the implications for practice and future research, of a 2018 Cochrane systematic review that evaluated the efficacy and safety of blue light-filtering IOLs for providing protection to macular health and function. OBSERVATIONS: The Cochrane systematic review included 51 randomized controlled trials that were performed in 17 countries. The trials involved adults undergoing cataract surgery in which a blue light-filtering IOL was compared with an equivalent non-blue light-filtering IOL. Study follow-up periods ranged from 1 month to 5 years. Together, these studies considered clinical outcomes in more than 5000 eyes. There was limited ability to combine data across trials (to draw overall conclusions) because of the use of different measurement techniques for outcomes, incomplete reporting of data, and/or varied follow-up periods. We identified substantial shortcomings in the internal validity of many of the included studies, particularly regarding trial design, conduct, and reporting. We propose several avenues for improving the rigor of potential future research in the field, including developing a core set of outcome measures, the inclusion of sample size calculations, the masking of trial participants and outcome assessors, and prospective clinical trial registration. CONCLUSIONS AND RELEVANCE: Using blue light-filtering IOLs to impart benefits to the macula is currently not supported by the best available clinical research evidence, and it is important that clinicians are mindful of this evidence limitation when adopting these devices in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。